恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较

doi:10.11904/j.issn.1002-3070.2022.01.004

摘要/Abstract

摘要： 目的探讨恩度静脉持续泵入与滴注联合含铂双药方案一线化疗治疗晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的临床疗效与安全性。方法选取武汉大学人民医院2011年12月—2020年12月收治的100例病理分型为腺癌的晚期NSCLC患者作为研究对象,观察组为恩度静脉持续泵入(CIV)组,采取恩度静脉持续泵入联合培美曲塞+奈达铂化疗方案进行治疗,共50例;对照组为恩度静脉滴注(DIV)组,采取恩度静脉持续滴注联合培美曲塞+奈达铂化疗方案进行治疗,共50例。比较两组患者总有效率(Overall response rate,ORR)、疾病控制率(Disease control rate,DCR)、毒副反应发生情况,并分析晚期NSCLC患者无进展生存期(Progress-free survival,PFS)的影响因素。结果观察组ORR为38.0%,高于对照组的18.0%,差异有统计学意义(P=0.026)。观察组DCR为92.0%,高于对照组的74.0%,差异有统计学意义(P=0.017)。毒副反应发生情况比较无统计学差异(P＞0.05)。Cox回归分析结果表明,给药方式不是晚期NSCLC患者PFS的影响因素(P=0.340),放疗为晚期NSCLC患者PFS的独立影响因素(P＜0.05),接受了放疗的患者PFS长于未接受放疗的患者(HR=1.708,95% CI:1.041~2.801)。结论恩度静脉持续泵入联合含铂双药方案一线化疗治疗晚期NSCLC患者的ORR及DCR高于恩度静脉持续滴注联合含铂双药方案,且不会加重相关毒副作用,其中接受放疗的患者肿瘤进展风险低于未接受放疗的患者。

关键词: 非小细胞肺癌, 恩度, 静脉持续泵入, 静脉滴注, 含铂双药化疗

Abstract: Objective The objective of this study was to investigate the clinical efficacy and safety of intravenous continuous pumping and infusion of Endostar combined with platinum-containing dual-drug regimen as first-line chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 100 advanced NSCLC patients with pathological classification of adenocarcinoma who were admitted to Renmin Hospital of Wuhan University from December 2011 to December 2020 were selected as the research objects.The observation group was the CIV group,a total of 50 patients in the group were treated with Endostar intravenous continuous pumping combined with pemetrexed and nedaplatin.The control group was the DIV group,with the other 50 patients treated with Endostar intravenous infusion combined with pemetrexed and nedaplatin chemotherapy regimen.The overall response rate(ORR),disease control rate(DCR),and the occurrence of toxic and side effects between the two groups of patients were compared.Results The ORR of the observation group was 38.0%,which was higher than that of the control group(18.0%).The difference was statistically significant(P=0.026).The DCR of the observation group was 92.0%,which was higher than that of the control group(74.0%),and the difference was statistically significant(P=0.017).The occurrence of toxic and side effects was not statistically significant(P＞0.05).The results of Cox regression analysis showed that the method of administration was not a factor influencing progression-free survival(PFS)in patients with advanced NSCLC(P=0.340),and radiotherapy was an independent factor affecting PFS in patients with advanced NSCLC(P＜0.05).The PFS of patients who received radiotherapy was longer than that of patients who did not receive radiotherapy(HR=1.708,95% CI:1.041~2.801).Conclusion The ORR and DCR of patients with advanced NSCLC treated with continuous intravenous pumping combined with first-line chemotherapy with platinum-containing two-drug regimen were higher than those treated with intravenous infusion,without aggravating related toxic and side effects.Among them,the risk of tumor progression in patients receiving radiotherapy was lower than that in patients not receiving radiotherapy.

Key words: Non-small cell lung cancer, Endostar, Continuous intravenous pumping, Intravenous infusion, Platinum-containing dual-drug chemotherapy

中图分类号:

R734.2

张梦茹, 曹德东, 戈伟. 恩度静脉持续泵入与滴注联合含铂双药方案化疗治疗晚期非小细胞肺癌的疗效与安全性比较[J]. 实用肿瘤学杂志, 2022, 36(1): 20-25.

ZHANG Mengru, CAO Dedong, GE Wei. Comparison of efficacy and safety of Endostar intravenous continuous pumping and dripping combined with platinum-containing dual-drug regimen chemotherapy for the treatment of advanced non-small cell lung cancer[J]. Journal of Practical Oncology, 2022, 36(1): 20-25.

参考文献

1 Global Burden of Disease Cancer Collaboration,Fitzmaurice C,Akinyemiju TF,et al.Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2016:a systematic analysis for the global burden of disease study[J].JAMA Oncol,2018,4(11):1553-1568.
2 Ettinger DS,Wood DE,Aggarwal C,et al.NCCN Guidelines Insights:Non-Small cell lung cancer,version 1.2020[J].J Natl Compr Canc Netw,2019,17(12):1464-1472.
3 D'Addario G,Pintilie M,Leighl NB,et al.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:a meta-analysis of the published literature[J].J Clin Oncol,2005,23(13):2926-2936.
4 Ling Y,Yang Y,Lu N,et al.Endostar,a novel recombinant human endostatin,exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells[J].Biochem Biophys Res Commun,2007,361(1):79-84.
5 Han BH,Xiu QY,Wang HM,et al.A multicenter,randomized,double-blind,placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin(PC)alone or combined with endostar for advanced non-small cell lung cancer(NSCLC)[J].Zhonghua Zhong Liu Za Zhi,2011,33(11):854-859.
6 Eisenhauer EA,Therasse P,Boqaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
7 Zhou JG,Tian X,Wang X,et al.Treatment on advanced NSCLC:platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone A systematic review and meta-analysis of randomised controlled trials[J].Med Oncol,2015,32(2):471.
8 Rossi A,Di Maio M.Platinum-based chemotherapy in advanced non-small-cell lung cancer:optimal number of treatment cycles[J].Expert Rev Anticancer Ther,2016,16(6):653-660.
9 Weitzner O,Yagur Y,Kadan Y,et al.Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy[J].Oncologist,2019,24(12):1471-1475.
10 Peters S,Adjei AA.Lung cancer.How much platinum-based chemotherapy is enough in NSCLC?[J].Nat Rev Clin Oncol,2015,12(1):8-10.
11 Xiong Y,Huang BY,Yin JY.Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer:focusing on DNA repair systems[J].Med Oncol,2017,34(4):48.
12 王艳,张申众,袁秀敏,等.奈达铂分别联合紫杉醇和培美曲塞一线治疗肺腺癌的临床效果比较[J].中国医药指南,2020,18(12):177-178.
13 刘林夕,杜雨蒙,王晓晨.比较奈达铂分别联合紫杉醇和培美曲塞治疗晚期肺腺癌效果[J].世界复合医学,2021,7(1):126-128.
14 汪淼.奈达铂联合培美曲塞对晚期肺腺癌的疗效[J].当代临床医刊,2021,34(1):56.
15 Li X,Gu G,Soliman F,et al.The evaluation of durative transfusion of endostar combined with chemotherapy in patients with advanced non-small cell lung cancer[J].Chemotherapy,2018,63(4):214-219.
16 Wang J,Gu LJ,Fu CX,et al.Endostar combined with chemotherapy compared with chemotherapy alone in the treatment of nonsmall lung carcinoma:A meta-analysis based on Chinese patients[J].Indian J Cancer,2014,51(Suppl 3):106-109.
17 Rong B,Yang S,Li W,et al.Systematic review and meta-analysis of Endostar(rh-endostatin)combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer[J].World J Surg Oncol,2012,10:170.
18 An J,Lv W.Endostar(rh-endostatin)versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer:A meta-analysis[J].Thorac Cancer,2018,9(5):606-612.
19 崔佳宁,王俊杰.免疫治疗联合放疗治疗晚期非小细胞肺癌的进展[J].现代肿瘤医学,2018,26(15):2477-2480.
20 Teicher BA,Holden SA,Ara G,et al.Influence of an anti-angiogenic treatment on 9L gliosarcoma:oxygenation and response to cytotoxic therapy[J].Int J Cancer,1995,61(5):732-737.
21 袁岳宏,徐可,郑文川,等.恩度联合全脑放疗一线治疗非小细胞肺癌多发脑转移的临床研究[J].肿瘤学杂志,2021,27(9):722-727.
22 马红莲,彭芳,翟医蕊,等.不可手术局部晚期NSCLC隔周恩度联合同步放化疗多中心五年生存分析[J].中华放射肿瘤学杂志,2021,30(1):23-28.
23 杨晓军,李强,庄翔,等.VEGFR基因表达与接受恩度治疗的Ⅲa期非小细胞肺癌疗效相关性研究[J].肿瘤预防与治疗,2016,29(6):320-322.
24 Meng FJ,Wang S,Yan YJ,et al.Recombined humanized endostatin-induced suppression of HMGB1 expression inhibits proliferation of NSCLC cancer cells[J].Thorac Cancer,2019,10(1):90-95.
25 Wang B,Xu L,Li Q,et al.Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC:a systematic review and meta-analysis including non-randomized studies[J].BMC Cancer,2020,20(1):1021.
26 Chen Z,Luo Q,Zho Z,et al.Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression[J].Oncotarget,2017,8(45):79703-79711.
27 Zhao X,Wen X,Wei W,et al.Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA(N2)NSCLC[J].Cancer Biomark,2017,21(1):169-177.
28 Li X,Gu G,Soliman F,et al.The evaluation of durative transfusion of endostar combined with chemotherapy in patients with advanced non-small cell lung cancer[J].Chemotherapy,2018,63(4):214-219.

[1]	罗雯, 贾莉, 张佳文, 王冬杰, 孔英君. circRNA MYO1C对肺癌细胞自噬和肿瘤干细胞分化的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 500-505.
[2]	汪叶, 尚乃舰. 影像组学在非小细胞肺癌诊疗中的应用进展[J]. 实用肿瘤学杂志, 2021, 35(5): 485-488.
[3]	王俊美, 潘慧卿, 李婧铱, 贾迪, 赵炜明, 吕昌莲. MT2-MMP在Ⅱ期肺腺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2021, 35(3): 243-247.
[4]	尹蕾, 杨旭东, 杨悦, 牛星鉴, 周晓平, 姬宏飞, 王一然. 中性粒细胞与淋巴细胞比值在非小细胞肺癌患者预后评估中的临床意义及相关机制研究[J]. 实用肿瘤学杂志, 2021, 35(2): 117-124.
[5]	董程(综述),段勇(审校). Dickkopf家族蛋白在非小细胞肺癌中的作用机制和治疗应用的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 64-68.
[6]	闫䶮, 侯利芳, 李任飞, 闫鹏, 王月东, 郑玉婷. ^99mTc-HYNIC-MPG在体非小细胞肺癌分子分型研究[J]. 实用肿瘤学杂志, 2020, 34(5): 412-417.
[7]	孙亚娟, 姜智允, 尚乃舰, 孙庆鑫, 陆佩欧. 双源CT能量成像在评估非小细胞肺癌纵隔淋巴结转移中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(6): 531-535.
[8]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[9]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[10]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[11]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[12]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[13]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[14]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[15]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.